Literature DB >> 25917628

Strategies to relieve immunosuppression in pancreatic cancer.

Max Schnurr1, Peter Duewell, Christian Bauer, Simon Rothenfusser, Kirsten Lauber, Stefan Endres, Sebastian Kobold.   

Abstract

Despite continuous progress in the understanding of deregulated pathways in pancreatic cancer cells and development of targeted therapies, therapeutic advances with clinical benefit have been scarce over the last decades. The recent success of immunotherapy for some solid cancers has fueled optimism that this approach might also work for pancreatic cancer. However, a highly immunosuppressive microenvironment mediated by tumor, stromal and immune cells creates a major hurdle for immunotherapy. Mouse models have helped to unravel critical immunosuppressive mechanisms that could serve as novel therapeutic targets. Here we review new promising strategies that alone or in combination with other modalities, such as chemotherapy or irradiation, have the potential to lead to tumor immune control and finally better clinical outcome.

Entities:  

Keywords:  adoptive cellular therapy; immunotherapy; innate immunity; pancreatic cancer; radiotherapy; review; tumor stroma; vaccination

Mesh:

Year:  2015        PMID: 25917628     DOI: 10.2217/imt.15.9

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  10 in total

1.  Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer.

Authors:  Li Xiao; Ulrike Erb; Kun Zhao; Thilo Hackert; Margot Zöller
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

2.  Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.

Authors:  Anne M Noonan; Matthew R Farren; Susan M Geyer; Ying Huang; Sanaa Tahiri; Daniel Ahn; Sameh Mikhail; Kristen K Ciombor; Shubham Pant; Santiago Aparo; Jennifer Sexton; John L Marshall; Thomas A Mace; Christina S Wu; Bassel El-Rayes; Cynthia D Timmers; James Zwiebel; Gregory B Lesinski; Miguel A Villalona-Calero; Tanios S Bekaii-Saab
Journal:  Mol Ther       Date:  2016-04-04       Impact factor: 11.454

3.  Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation.

Authors:  Hester J Scheffer; Anita G M Stam; Bart Geboers; Laurien G P H Vroomen; Alette Ruarus; Beaunelle de Bruijn; M Petrousjka van den Tol; Geert Kazemier; Martijn R Meijerink; Tanja D de Gruijl
Journal:  Oncoimmunology       Date:  2019-08-28       Impact factor: 8.110

Review 4.  Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.

Authors:  Michael Orth; Philipp Metzger; Sabine Gerum; Julia Mayerle; Günter Schneider; Claus Belka; Maximilian Schnurr; Kirsten Lauber
Journal:  Radiat Oncol       Date:  2019-08-08       Impact factor: 3.481

5.  Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells.

Authors:  Jinthe Van Loenhout; Tal Flieswasser; Laurie Freire Boullosa; Jorrit De Waele; Jonas Van Audenaerde; Elly Marcq; Julie Jacobs; Abraham Lin; Eva Lion; Heleen Dewitte; Marc Peeters; Sylvia Dewilde; Filip Lardon; Annemie Bogaerts; Christophe Deben; Evelien Smits
Journal:  Cancers (Basel)       Date:  2019-10-19       Impact factor: 6.639

6.  Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma.

Authors:  Carole Siret; Aurélie Collignon; Françoise Silvy; Stéphane Robert; Thierry Cheyrol; Perrine André; Véronique Rigot; Juan Iovanna; Serge van de Pavert; Dominique Lombardo; Eric Mas; Anna Martirosyan
Journal:  Front Immunol       Date:  2020-01-22       Impact factor: 7.561

7.  Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer.

Authors:  Daniel Cui Zhou; Reyka G Jayasinghe; Siqi Chen; John M Herndon; Michael D Iglesia; Pooja Navale; Michael C Wendl; Wagma Caravan; Kazuhito Sato; Erik Storrs; Chia-Kuei Mo; Jingxian Liu; Austin N Southard-Smith; Yige Wu; Nataly Naser Al Deen; John M Baer; Robert S Fulton; Matthew A Wyczalkowski; Ruiyang Liu; Catrina C Fronick; Lucinda A Fulton; Andrew Shinkle; Lisa Thammavong; Houxiang Zhu; Hua Sun; Liang-Bo Wang; Yize Li; Chong Zuo; Joshua F McMichael; Sherri R Davies; Elizabeth L Appelbaum; Keenan J Robbins; Sara E Chasnoff; Xiaolu Yang; Ashley N Reeb; Clara Oh; Mamatha Serasanambati; Preet Lal; Rajees Varghese; Jay R Mashl; Jennifer Ponce; Nadezhda V Terekhanova; Lijun Yao; Fang Wang; Lijun Chen; Michael Schnaubelt; Rita Jui-Hsien Lu; Julie K Schwarz; Sidharth V Puram; Albert H Kim; Sheng-Kwei Song; Kooresh I Shoghi; Ken S Lau; Tao Ju; Ken Chen; Deyali Chatterjee; William G Hawkins; Hui Zhang; Samuel Achilefu; Milan G Chheda; Stephen T Oh; William E Gillanders; Feng Chen; David G DeNardo; Ryan C Fields; Li Ding
Journal:  Nat Genet       Date:  2022-08-22       Impact factor: 41.307

8.  On the analysis of clonogenic survival data: Statistical alternatives to the linear-quadratic model.

Authors:  Steffen Unkel; Claus Belka; Kirsten Lauber
Journal:  Radiat Oncol       Date:  2016-01-28       Impact factor: 3.481

9.  Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors.

Authors:  Ying Zhang; Hildegund C J Ertl
Journal:  Oncotarget       Date:  2016-04-26

Review 10.  The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.

Authors:  Yaojie Fu; Shanshan Liu; Shan Zeng; Hong Shen
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.